Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $7.50

Trevi Therapeutics (NASDAQ:TRVI) had its price target lifted by HC Wainwright from $6.00 to $7.50 in a research report sent to investors on Thursday morning, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Trevi Therapeutics’ FY2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.38) EPS.

A number of other equities analysts also recently commented on the company. Leerink Partners began coverage on Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price for the company. D. Boral Capital restated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday. Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Finally, EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $4.17 on Thursday. The business’s fifty day moving average price is $2.99 and its 200 day moving average price is $2.93. Trevi Therapeutics has a 12-month low of $1.22 and a 12-month high of $4.60.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the prior year, the company posted ($0.08) EPS. As a group, research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Logos Global Management LP increased its stake in Trevi Therapeutics by 27.3% during the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after buying an additional 600,000 shares during the period. Vanguard Group Inc. raised its holdings in Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after purchasing an additional 60,249 shares in the last quarter. Ally Bridge Group NY LLC acquired a new stake in Trevi Therapeutics in the second quarter worth approximately $4,395,000. MAI Capital Management boosted its stake in Trevi Therapeutics by 0.7% during the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after purchasing an additional 8,789 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Trevi Therapeutics by 10.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after purchasing an additional 117,418 shares during the period. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.